These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 33299059)

  • 1. Melphalan 200 mg/m
    Brioli A; Vom Hofe F; Rucci P; Ernst T; Yomade O; Hilgendorf I; Scholl S; Sayer H; Mügge LO; Hochhaus A; von Lilienfeld-Toal M
    Bone Marrow Transplant; 2021 May; 56(5):1209-1212. PubMed ID: 33299059
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of melphalan 140 mg/m(2) vs 200 mg/m(2) on toxicities and outcomes in multiple myeloma patients undergoing single autologous stem cell transplantation-a single center experience.
    Katragadda L; McCullough LM; Dai Y; Hsu J; Byrne M; Hiemenz J; May S; Cogle CR; Norkin M; Brown RA; Wingard JR; Chang M; Moreb JS
    Clin Transplant; 2016 Aug; 30(8):894-900. PubMed ID: 27219740
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BEAM Conditioning Regimen Has Higher Toxicity Compared With High-Dose Melphalan for Salvage Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma.
    Veeraputhiran M; Jain T; Deol A; Ayash L; Kim S; Dyson G; Bhutani D; Lum LG; Ratanatharathorn V; Uberti JP; Abidi MH
    Clin Lymphoma Myeloma Leuk; 2015 Sep; 15(9):531-5. PubMed ID: 26166312
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessing Outcomes in Patients With Multiple Myeloma Postautologous Stem Cell Transplantation: Contrasting the Effects of Melphalan Dosages at 200 mg/m
    Brown Z; Scott C; Zhang LF; Sadek R; Clarke A; Jillella A; Keruakous AR; Clemmons AB
    Clin Lymphoma Myeloma Leuk; 2024 Sep; 24(9):642-647. PubMed ID: 38845275
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravenous busulfan and melphalan as a conditioning regimen for autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: a matched comparison to a melphalan-only approach.
    Blanes M; Lahuerta JJ; González JD; Ribas P; Solano C; Alegre A; Bladé J; San Miguel JF; Sanz MA; de la Rubia J
    Biol Blood Marrow Transplant; 2013 Jan; 19(1):69-74. PubMed ID: 22897964
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical factors associated with autologous stem cell transplantation outcomes in multiple myeloma: upfront transplant with MEL200 remains the standard of care.
    Bostankolu Değirmenci B; Yegin ZA; Akdemir ÜÖ; Dede A; Gündem GG; Özkurt ZN; Atay LÖ; Yağcı M
    Ann Hematol; 2024 Jan; 103(1):269-283. PubMed ID: 37880484
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Autologous stem cell transplantation in first remission is associated with better progression-free survival in multiple myeloma.
    Aggarwal M; Agrawal N; Yadav N; Verma P; Ahmed R; Mehta P; Kapoor J; Bhurani D
    Ann Hematol; 2018 Oct; 97(10):1869-1877. PubMed ID: 29781040
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Busulfan plus melphalan versus high-dose melphalan as a conditioning regimen for autologous stem cell transplantation in multiple myeloma with high-risk features (KMM 2015).
    Kim M; Lee JJ; Min CK; Lee JY; Jo JC; Yoon SS; Lim SN; Do YR; Kim K; Lee JH; Yoo KH; Bae SH; Yi JH; Jung J; Eom HS; Jung SH
    Ann Hematol; 2023 Aug; 102(8):2233-2240. PubMed ID: 37392367
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Full or intensity-reduced high-dose melphalan and single or double autologous stem cell transplant with or without bortezomib consolidation in patients with newly diagnosed multiple myeloma.
    Straka C; Salwender H; Knop S; Vogel M; Müller J; Metzner B; Langer C; Sayer H; Jung W; Dürk HA; Bassermann F; Gramatzki M; Rösler W; Wolf HH; Brugger W; Engelhardt M; Fischer T; Liebisch P; Einsele H
    Eur J Haematol; 2021 Nov; 107(5):529-542. PubMed ID: 34270825
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.
    Gay F; Oliva S; Petrucci MT; Conticello C; Catalano L; Corradini P; Siniscalchi A; Magarotto V; Pour L; Carella A; Malfitano A; Petrò D; Evangelista A; Spada S; Pescosta N; Omedè P; Campbell P; Liberati AM; Offidani M; Ria R; Pulini S; Patriarca F; Hajek R; Spencer A; Boccadoro M; Palumbo A
    Lancet Oncol; 2015 Dec; 16(16):1617-29. PubMed ID: 26596670
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [A Propensity Score Matching Study of Autologous Hematopoietic Stem Cell Transplantation and New Drug Chemotherapy for Newly Diagnosed Multiple Myeloma].
    Yang FY; Wang HF; Xia LH; Wang QQ; Qian CJ; He J
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Feb; 30(1):158-165. PubMed ID: 35123620
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Melphalan dose in myeloma patients ≥65 years of age undergoing high-dose therapy and autologous stem cell transplantation: a multicentric observational registry study.
    Ghilardi G; Pabst T; Jeker B; Müller R; Cairoli A; Müller AMS; Bargetzi M; Hitz F; Baldomero H; Heim D; Schmidt A; Rossi D; Ghielmini M; Wannesson L; Lerch E; Samaras P; Schanz U; Passweg JR; Stussi G; Kleber M; Gerber B;
    Bone Marrow Transplant; 2019 Jul; 54(7):1029-1037. PubMed ID: 30390061
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Conditioning with melphalan 200 mg/m
    Afram G; Chaireti R; Uttervall K; Luong V; Lund J; Kashif M; Gahrton G; Alici E; Nahi H
    Eur J Haematol; 2022 Dec; 109(6):749-754. PubMed ID: 36066204
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Busulfan, melphalan, and bortezomib compared to melphalan as a high dose regimen for autologous hematopoietic stem cell transplantation in multiple myeloma: long term follow up of a novel high dose regimen.
    Hagen P; D'Souza A; Hari P; Davila O; Zhang MJ; Vesole DH; Smith SE; Rodriguez TE; Stiff PJ
    Leuk Lymphoma; 2020 Dec; 61(14):3484-3492. PubMed ID: 32865474
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Second autologous stem cell transplant: an effective therapy for relapsed multiple myeloma.
    Singh Abbi KK; Zheng J; Devlin SM; Giralt S; Landau H
    Biol Blood Marrow Transplant; 2015 Mar; 21(3):468-72. PubMed ID: 25529381
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Conditioning regimens in autologous stem cell transplantation for multiple myeloma: a comparative study of efficacy and toxicity from the Spanish Registry for Transplantation in Multiple Myeloma.
    Lahuerta JJ; Martinez-Lopez J; Grande C; Bladé J; de la Serna J; Alegre A; García-Laraña J; Caballero D; Sureda A; de la Rubia J; Alvarez AM; Marín J; Escudero A; Conde E; Perez-Equiza K; García Ruiz JC; Moraleda JM; León A; Bargay J; Cabrera R; Hernandez-García MT; Diaz-Mediavilla J; Miguel JS
    Br J Haematol; 2000 Apr; 109(1):138-47. PubMed ID: 10848793
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Survival outcomes following autologous stem cell transplant with melphalan 140mg/m
    Sharma N; Benson E; Zhao Q; Nunnelee J; Cottini F; Elder P; Rosko A; Bumma N; Khan A; Umyarova E; Devarakonda S; Efebera YA; Benson DM
    Leuk Lymphoma; 2023; 64(7):1315-1321. PubMed ID: 37199099
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase 1/2 of carfilzomib and melphalan conditioning for autologous stem cell transplantation for multiple myeloma (CARAMEL).
    Visram A; Hayman SR; Dispenzieri A; Kapoor P; Lacy MQ; Gertz MA; Buadi FK; Dingli D; Warsame R; Kourelis T; Cook J; Binder M; Gonsalves W; Muchtar E; Leung N; Roy V; Rajkumar SV; Kumar S
    Am J Hematol; 2023 Aug; 98(8):1277-1285. PubMed ID: 37334773
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized study of melphalan 200 mg/m(2) vs 280 mg/m(2) as a preparative regimen for patients with multiple myeloma undergoing auto-SCT.
    Bensinger WI; Becker PS; Gooley TA; Chauncey TR; Maloney DG; Gopal AK; Green DJ; Press OW; Lill M; Ifthikharuddin JJ; Vescio R; Holmberg LA; Phillips GL
    Bone Marrow Transplant; 2016 Jan; 51(1):67-71. PubMed ID: 26367217
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Phase IIb, Multicenter, Open-Label, Safety, and Efficacy Study of High-Dose, Propylene Glycol-Free Melphalan Hydrochloride for Injection (EVOMELA) for Myeloablative Conditioning in Multiple Myeloma Patients Undergoing Autologous Transplantation.
    Hari P; Aljitawi OS; Arce-Lara C; Nath R; Callander N; Bhat G; Allen LF; Stockerl-Goldstein K
    Biol Blood Marrow Transplant; 2015 Dec; 21(12):2100-2105. PubMed ID: 26327631
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.